Results 131 to 140 of about 20,409 (197)

Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera. [PDF]

Blood Adv
Sørensen AL, Skov V, Kjær L, Bjørn ME, Eickhardt-Dalbøge CS, Larsen MK, Nielsen CH, Thomsen C, Rahbek Gjerdrum LM, Knudsen TA, Ellervik C, Overgaard UM, Andersen CL, Hasselbalch H.   +13 more
europepmc   +1 more source

Predictive model for HBsAg clearance rate in chronic hepatitis B patients treated with pegylated interferon α-2b for 48 weeks. [PDF]

Hepatol Int
Tan Z, Kong N, Zhang Q, Gao X, Shang J, Geng J, You R, Wang T, Guo Y, Wu X, Zhang W, Qu L, Zhang F.   +12 more
europepmc   +1 more source

A predictive model for functional cure in chronic HBV patients treated with pegylated interferon alpha: a comparative study of multiple algorithms based on clinical data. [PDF]

Virol J
Ye YM, Lin Y, Sun F, Yang WY, Zhou L, Lin C, Pan C.   +6 more
europepmc   +1 more source

Recurrence risk factors for chronic hepatitis B virus-infected patients who achieve functional cure with pegylated interferon-α-2b-based therapy: a multicenter pilot study. [PDF]

Virol J
Chang LJ, Hao CQ, Rao GR, Xu LL, Li J, Cheng Y, Zheng LJ, Wu CW, Chen HX, Chen ZR, Lian JQ, Wu SH, Luo LM, Zhang WL, Zhang Y.   +14 more
europepmc   +1 more source

Predicting clinical outcomes in chronic hepatitis B patients receiving nucleoside analogues and pegylated interferon alpha: a hematochemical and clinical analysis. [PDF]

BMC Infect Dis
Xu S, Ye XT, Zhang D, Dong P, Wu YH, Pan CW.   +5 more
europepmc   +1 more source

Results of Response-Guided Therapy with Pegylated Interferon Alpha 2a in Chronic Hepatitis B and D. [PDF]

Trop Med Infect Dis
Gherlan GS, Lazar SD, Culinescu A, Smadu D, Vatafu AR, Popescu CP, Florescu SA, Ceausu E, Calistru PI.   +8 more
europepmc   +1 more source

Safety and efficacy of 48-week pegylated interferon-α-2b therapy in patients with hepatitis B virus-related compensated liver cirrhosis: a pilot observational study. [PDF]

Front Med (Lausanne)
Wang Z, Wang X, Zhou L, Shi S, Hua Y, Feng Y.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Pegylated interferons

Clinics in Liver Disease, 2003
In summary, pegylated IFNs have a longer half-life, reduced immunogenicity, better pharmacokinetics, and enhanced biological activity when compared with standard IFN. Better adherence rates are feasible because of the once weekly administration of pegylated IFN. The adverse event profile is largely comparable. The improved pharmacokinetics of pegylated
Umaprasanna S, Karnam, K Rajender, Reddy
openaire   +4 more sources

Pegylated interferons for chronic hepatitis B

Antiviral Research, 2003
Conventional interferon therapy has been used for the treatment of chronic hepatitis B (CHB) for many decades. However, the use of interferon has been limited by its short half-life and high incidence of dose-related side effects. A meta-analysis investigating the short- and long-term consequences of interferon therapy showed that, whilst interferon ...
Craxi, A., Cooksley, W. G.
openaire   +4 more sources